依奇珠单抗达到国家银屑病基金会治疗目标的汇总分析
该事后分析汇总4项III期临床试验,评估依奇珠单抗治疗斑块状银屑病达到国家银屑病基金会(NPF)治疗目标的能力。UNCOVER试验中,依奇珠单抗每2周组第12周可接受应答率和目标应答率分别为73.9%和51.8%;IXORA-S试验中依奇珠单抗每2周组目标应答率显著高于乌司奴单抗(50.7% vs 24.1%,P < .0001)。结论为多数接受依奇珠单抗治疗的患者达到NPF以患者为中心的治疗目标。
要点
- 依奇珠单抗每2周治疗第12周可接受应答率73.9%,目标应答率51.8%。
- 依奇珠单抗目标应答率显著优于乌司奴单抗(50.7% vs 24.1%,P < .0001)。
- 数据来自对照研究,可能不代表真实世界实践。
核心结论
- 多数接受依奇珠单抗治疗的患者在4项III期临床试验中达到NPF以患者为中心的治疗目标。
研究设计与样本
- 对4项III期临床试验(UNCOVER-1、-2、-3和IXORA-S)的汇总数据进行事后分析。
- UNCOVER试验样本量n=2701,IXORA-S试验样本量n=302。
主要发现
- UNCOVER试验第12周,依奇珠单抗80 mg每2周组可接受应答率73.9%、目标应答率51.8%;依那西普50 mg组分别为35.7%和14.9%;安慰剂组分别为3.0%和0.6%。
- IXORA-S试验第12周,依奇珠单抗每2周组可接受应答率68.4%、目标应答率50.7%,均显著高于乌司奴单抗组的38.6%和24.1%(P < .0001)。
关键数值与推荐
- NPF定义的可接受应答:治疗12周时受累体表面积(BSA)≤3%或BSA改善≥75%。
- NPF定义的目标应答:治疗12周时BSA≤1%,且此后每6个月维持BSA≤1%。
临床怎么用
- 依奇珠单抗治疗斑块状银屑病可帮助多数患者达到NPF可接受和目标应答标准。
局限性
- 数据来自对照研究,可能不能反映真实世界实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The National Psoriasis Foundation (NPF) published treatment targets for US patients with plaque psoriasis. However, data are lacking on how well existing therapies help achieve these goals. OBJECTIVE: To examine the ability of an interleukin 17 inhibitor, ixekizumab, in achieving these treatment targets. METHODS: Post hoc analysis was performed on pooled data from 4 phase III clinical trials assessing ixekizumab for plaque psoriasis: the UNCOVER-1, -2, and -3 trials and the IXORA-S trial. Treatment response was evaluated using the NPF-defined acceptable response (affected body surface area [BSA] of 3% or less or BSA improvement of 75% or higher at 12 weeks of treatment) and target response (BSA of 1% or less at 12 weeks and every 6 months thereafter). RESULTS: In the UNCOVER trials (n = 2701), acceptable and target response rates at week 12 were 73.9% and 51.8% with ixekizumab 80 mg every 2 weeks, 35.7% and 14.9% with etanercept 50 mg, and 3.0% and 0.6% with placebo, respectively. In the IXORA-S trial (n = 302), acceptable and target response rates at week 12 were significantly higher with ixekizumab every 2 weeks versus ustekinumab (acceptable response 68.4% vs 38.6%, P < .0001; target response 50.7% vs 24.1%, P < .0001). LIMITATIONS: Data were from controlled studies and may not reflect real-world practice. CONCLUSION: The majority of patients treated with ixekizumab in 4 phase III clinical trials achieved NPF, patient-centered treatment targets.
引用
- Armstrong A, Amato D, Huster W, et al. Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies. J Am Acad Dermatol. 2019. PMID: 31562945. doi:10.1016/j.jaad.2019.09.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。